Biomarker results from the KGOG3056/NIRVANA-R trial: Maintenance niraparib plus bevacizumab in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor.
See something others should know about? Email CHS or call/txt (206) 399-5959. You can view recent CHS 911 coverage here. Hear sirens and wondering what’s going on? Check out reports ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results